Premium
Quality‐adjusted life years in cancer: pros, cons, and alternatives
Author(s) -
WOODWARD R.M.,
MENZIN J.,
NEUMANN P.J.
Publication year - 2013
Publication title -
european journal of cancer care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 67
eISSN - 1365-2354
pISSN - 0961-5423
DOI - 10.1111/ecc.12006
Subject(s) - medicine , reimbursement , quality of life (healthcare) , value (mathematics) , quality adjusted life year , cancer , quality (philosophy) , value of life , actuarial science , cons , health care , risk analysis (engineering) , cost effectiveness , nursing , economic growth , economics , programming language , philosophy , epistemology , machine learning , computer science , microeconomics
WOODWARD R.M., MENZIN J. & NEUMANN P.J. (2013) European Journal of Cancer Care 22 , 12–19 Quality‐adjusted life years in cancer: pros, cons, and alternatives High and rising cancer treatment costs have forced a discussion about the use of cost‐effectiveness analyses and other approaches to assess the value of cancer care. Oncologists have traditionally resisted using economic considerations in day‐to‐day medical considerations, though unavoidably their decisions have important resource implications, and increasingly economic realities are impacting their actions. In this paper, we summarise the use of the quality‐adjusted life years to assess the value of cancer care and suggest potential ways to improve upon value measurement in cancer coverage and reimbursement decisions.